On February 22, 2023 Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, reported participation at the 43rd Annual Healthcare Conference being held March 6-8, 2023, in Boston, MA (Press release, Aadi Bioscience, FEB 22, 2023, View Source [SID1234627554]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Brendan Delaney, Aadi Bioscience CEO, will join in a panel discussion entitled, "Tumor Agnostic Development," on Wednesday, March 8, 2023 at 9:10 AM ET. Company management will also participate in one-on-one meetings with investors during the conference.

The panel presentation will be webcast live on the IR pages of the Aadi Biosciences website and will be available for replay for approximately 30 days following the presentation.